Table 2.
Relation Between Time at Risk (Number of Years Since Onset of Drug Injection) and HCV Prevalence in Injection Drug Users in 72 Studies and 293 Categories of Time at Risk, HCV Synthesis Project, 1989–2006
| Parameter | Estimate | SE | 95% CI |
|
| Lower Bound | Upper Bound | |||
| Intercept | −0.82 | 0.17 | −1.16 | −0.47 |
| Time at risk** | 0.18 | 0.01 | 0.16 | 0.20 |
| Centered quadratic time at risk** | −0.20 | 0.02 | −0.23 | −0.16 |
| Recruitment before 1995** | 0.72 | 0.22 | 0.28 | 1.16 |
| Developing/transitional country* | 1.10 | 0.38 | 0.35 | 1.84 |
Abbreviations: CI, confidence interval; HCV, hepatitis C virus; SE, standard error.
* P < 0.05; **P < 0.01; type III tests of fixed effects as estimated by generalized mixed-effects meta-regression.